News from CPhI

DSM cuts out China's ATS-8 intermediate middlemen with enzyme-made statin APIs

DSM makes statins like rosuvastatin, the API in Astrazeneca's Crestor, using enzymes

Royal DSM has launched a statin API it claims is made using a green production method that reduces reliance on intermediate suppliers.

The new active pharmaceutical ingredient (APIs) is a version of rosuvastatin, the active in AstraZeneca’s Crestor, that is produced using an enzymatic process that requires fewer solvents, and eliminates buthyl-lithuim entirely.

In addition to eliminating solvents, DSM claims “the technology eliminates the use of many harmful chemicals such as butyl-lithium and the dependency on a very limited number of ATS-8 intermediate suppliers.”

A spokesman for DSM Sinochem, an organistion set up with Sinochem in which DSM holds shares, told that: “At the moment the main ATS-8 manufacturers, which service the merchant market globally, are located in China.

He declined to name any of the Chinese suppliers, but did stress that: “We do not buy from any of them. We manufacture our own intermediate in our highly efficient production process.

He explained that: “Our innovative production process [which was runner up at the CPhI Innovation awards last week], uses our own enzyme DERA [deoxyribose phosphate aldolase] to efficiently manufacture our intermediate.”

The firm also claims that the enzymatic method results in a carbon footprint that is 35% lower than traditional approaches to statin manufacture and produces purer, more stable actives.


DSM has been involved in the development of enzymatic production methods for APIs for the past few years through partnerships with c-Lecta and Codexis, the latter of which has been developing a way of making ATS-8 using enzymes since 2006.

The agreement with Codexis, signed in 2011, was followed a year later by DSM’s receipt of Certification of Suitability to the Monograph of the European Pharmacopoeia (CEP) for generic atorvastatin.

However, according to the DSM Sinochem spokesman the new version of Rosuvastatin and indeed the version of enzymatically produced Atorvastatin also sold by the firm under its PureActives brand, relies on separate technology.

[This is] unrelated to the granting of the CEP for Atorva and also unrelated to any events with Codexis" he said, adding that "we do not use the Codexis enzyme for our statins."

Related News

Crestor Manufacturing, photo c/o AstraZeneca

AstraZeneca API plant set to shut by 2017 as Patent Cliff strikes again

DSM-Sinochem plant in Toansa India

Environmental group welcomes DSM-Sinochem and GSK efforts to halt spread of antibiotic resistance

DSM's Nutritional Products team in Spain to sell vitamin APIs to drugmakers

DSM's Nutritional Products team in Spain to sell vitamin APIs to drugmakers

DSM sees generics as high growth area

DSM says generics-focused partnering will drive pharma growth

Generic Lipitor drives jump in pharma revenues at Codexis

Generic Lipitor drives jump in pharma revenues at Codexis

Ranbaxys predicts atorvastatin shortages following manufacturing halt

Ranbaxy predicts shortages due to generic 'lipitor' manufacturing halt

Codexis, Shell, Pfizer, atorvastatin, API, job cuts,

Low demand for ‘Lipitor’ intermediate hits Codexis in Q2; job cuts expected

Codexis strengthens relationship with Merck & Co

Codexis strengthens relationship with Merck & Co

Related Products

See more related products